Medidata announced that Medidata Clinical Data Studio, its AI-powered data management solution and an integral part of the Medidata Data Experience, has seen a rise in adoption with many of the industry’s major players. In the past 18 months, biopharmaceutical companies and contract research organizations, including Eisai, Bioforum, ICON, Corcept Therapeutics, Everest Clinical Research, and ClinChoice have selected Clinical Data Studio to unify data review, improve trial oversight, and drive operational efficiency. “As clinical trials become more complex and data-intensive, life sciences organizations are under increasing pressure to unify their data and analytics strategies to drive smarter, faster decision-making,” said Nisarg Shah, practice director, Everest Group. “Medidata Clinical Data Studio is at the forefront of this transformation with a next-generation platform that seamlessly integrates AI, advanced analytics, and deep domain expertise. With its end-to-end capabilities, Medidata empowers sponsors to unlock the full potential of their clinical data, accelerating innovation throughout the drug development lifecycle.”
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DASTY:
- Challenging Market Conditions and Slow Product Transition Drive Sell Rating for Dassault Systemes
- Dassault Systemes price target lowered to EUR 27 from EUR 28 at Jefferies
- Jefferies analysts hold an analyst/industry conference call
- Cautious Outlook: Dassault Systemes’ Ambitious EPS Growth Targets Raise Concerns
- Medidata secures new enterprise agreements with several customers